Enter inventor name

Marvin R Garovoy

USPTO Granted Patents = 14 (Patent Applications = 7)

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 52(Granted Patents)

Location History:

San Anselmo, CA (US) (1999 - 2020)
Sausalito, CA (US) (2021 - 2024)

Company Filing History:

University of California

patents

2 out of 18

Applied Molecular Transport Inc.

5. 2 out of 832,912

Other

patents

Years Active: 1999-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11873525 - Methods of administering 3,4-diaminopridine (2024-01-16),

2. 11845977 - Methods of administering 3,4-diaminopridine (2023-12-19),

3. 11479593 - Compositions, formulations and interleukin production and purification (2022-10-25),

4. 11274332 - Methods of administering 3,4-diaminopyridine (2022-03-15),

5. 11274331 - Methods of administering 3,4-diaminopyridine (2022-03-15),

6. 11268128 - Methods of administering 3,4-diaminopyridine (2022-03-08),

7. 11160869 - Compositions, formulations and interleukin production and purification (2021-11-02),

8. 11060128 - Methods of administering 3,4-diaminopyridine (2021-07-13),

9. 10793893 - Methods of administering 3,4-diaminopyridine (2020-10-06),

10. 7364734 - Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist (2008-04-29),

11. 6652855 - Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist (2003-11-25),

12. 6582698 - Treatment method (2003-06-24),

13. 6410721 - Polynucleotide decoys that inhibit MHC-II expression and uses thereof (2002-06-25),

14. 5859226 - Polynucleotide decoys that inhibit MHC-II expression and uses thereof (1999-01-12),

Title: **Innovator Marvin R. Garovoy: A Pioneer in 3,4-Diaminopridine Applications**

Introduction

Marvin R. Garovoy, based in Sausalito, CA, is a distinguished inventor recognized for his substantial contributions to the field of pharmaceuticals. Holding 14 patents, Garovoy’s work centers around methods associated with 3,4-diaminopridine, a compound crucial for treating certain medical conditions. His innovative approaches have paved the way for advancements in the treatment of 3,4-DAP-sensitive diseases.

Latest Patents

Among his latest patents, Garovoy has developed several methods for administering 3,4-diaminopridine. These patents include techniques for determining NAT acetylation status of subjects with 3,4-DAP-sensitive diseases, as well as methods for selecting appropriate doses of 3,4-DAP based on this status. He provides methods for effectively administering 3,4-diaminopyridine or its pharmaceutically acceptable salts, along with comprehensive treatment strategies for patients in need.

Career Highlights

Garovoy's career is marked by his innovative approach to pharmaceutical research and development. His work is particularly notable in the context of 3,4-diaminopridine, highlighting his expertise in drug development and patient care. His patents reflect a deep understanding of pharmaceutical science and its practical applications in treating complex medical issues.

Collaborations

Throughout his career, Garovoy has collaborated with notable professionals, including Peter E. Haroldsen and Donald G. Musson. These collaborations have likely facilitated the growth of his research and expanded the reach of his innovations within the pharmaceutical industry.

Conclusion

Marvin R. Garovoy exemplifies the spirit of innovation in the pharmaceutical field. His extensive work with 3,4-diaminopridine underlines not only his inventiveness but also his dedication to advancing medical treatments. With a solid portfolio of patents and valuable collaborations, Garovoy continues to impact the industry positively, providing solutions for patients with 3,4-DAP-sensitive diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com